Wilmington PharmaTech, a CRDMO specializing in complex, custom active pharmaceutical ingredients (APIs) for small molecules, will drop $50 million to double its current production capacity at its Delaware facility.
The investment will add a pair of new 10,000-liter reactor suites designed to boost the Delaware site’s commercial‑scale manufacturing capabilities and support large‑scale production of small molecule drug ingredients and peptides, the company said in a March 23 press release.
The project is expected to wrap up by the third quarter of 2027. By that time, the workforce at the facility is expected to double, Wilmington added.
“Over the past decade, Wilmington has been among the few companies to actively invest in cGMP API manufacturing capacity in the U.S., including the recent addition of two new commercial-scale high-potency API suites,” Hui-Yin "Harry" Li, Ph.D., the company's founder and CEO, said in a statement. “This expansion builds on more than 20 years of cGMP manufacturing expertise and further strengthens our high-output scientific engine in solving complex chemistry challenges at scale.”
Funding for the expansion comes from an investment by Curewell Capital announced in October. Although an exact dollar amount wasn’t disclosed, the private equity group said its total outlay for Wilmington will likely reach into “nine figures.”
“Curewell Capital is proud to support Wilmington in expanding high-quality commercial API production in the U.S.,” Kent Payne, Ph.D., operating partner at Curewell and managing director at Wilmington, said in the company's release.
Wilmington, which was founded in 2003, operates out of a 54-acre campus in Newark, Delaware, where it hosts two adjacent facilities for production.